ATE186219T1 - Kombination von antihormonale und bindende moleküle zur krebsbehandlung - Google Patents

Kombination von antihormonale und bindende moleküle zur krebsbehandlung

Info

Publication number
ATE186219T1
ATE186219T1 AT93250090T AT93250090T ATE186219T1 AT E186219 T1 ATE186219 T1 AT E186219T1 AT 93250090 T AT93250090 T AT 93250090T AT 93250090 T AT93250090 T AT 93250090T AT E186219 T1 ATE186219 T1 AT E186219T1
Authority
AT
Austria
Prior art keywords
combination
antihormonal
binding molecules
cancer treatment
binding molecule
Prior art date
Application number
AT93250090T
Other languages
English (en)
Inventor
Beatrice C Langton
Original Assignee
Berlex Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE186219(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Berlex Biosciences filed Critical Berlex Biosciences
Application granted granted Critical
Publication of ATE186219T1 publication Critical patent/ATE186219T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93250090T 1993-03-24 1993-03-24 Kombination von antihormonale und bindende moleküle zur krebsbehandlung ATE186219T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93250090A EP0616812B1 (de) 1993-03-24 1993-03-24 Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung

Publications (1)

Publication Number Publication Date
ATE186219T1 true ATE186219T1 (de) 1999-11-15

Family

ID=8214259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93250090T ATE186219T1 (de) 1993-03-24 1993-03-24 Kombination von antihormonale und bindende moleküle zur krebsbehandlung

Country Status (7)

Country Link
EP (1) EP0616812B1 (de)
AT (1) ATE186219T1 (de)
DE (1) DE69326937T2 (de)
DK (1) DK0616812T3 (de)
ES (1) ES2141128T3 (de)
GR (1) GR3032511T3 (de)
PT (1) PT616812E (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DK1027437T3 (da) 1997-10-29 2008-11-24 Genentech Inc Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1
JP2001520885A (ja) 1997-10-29 2001-11-06 ジェネンテック・インコーポレーテッド Ｗｎｔ−１誘導遺伝子
ATE410512T1 (de) 1997-11-21 2008-10-15 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (de) 1997-12-12 2012-12-19 Genentech, Inc. Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
EP2075335A3 (de) 1998-12-22 2009-09-30 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
DK1897945T3 (da) 1999-12-23 2012-05-07 Genentech Inc IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
CA2397207C (en) 2000-01-13 2013-12-03 Genentech, Inc. Novel stra6 polypeptides
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
PT2000545E (pt) 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1575480A4 (de) 2002-02-22 2008-08-06 Genentech Inc Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
EP2289942B1 (de) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 Antikörper-Varianten
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
EP1553912A4 (de) 2002-06-07 2007-08-08 Genentech Inc Zusammensetzungen und verfahren f r die tumordiagnose und behandlung
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1578373A4 (de) 2002-09-11 2007-10-24 Genentech Inc Neue zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
US20060281146A1 (en) 2002-09-11 2006-12-14 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322200A3 (de) 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und Methoden für die Behandlung von immune verwandte Krankheiten
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
AU2003237792A1 (en) 2003-04-01 2004-11-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004101756A2 (en) 2003-05-09 2004-11-25 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP2784084B2 (de) 2003-07-08 2023-10-04 Novartis Pharma AG Heterologe IL-17A/F-Polypeptide und deren therapeutische Verwendungen
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK2295073T3 (da) 2003-11-17 2014-07-28 Genentech Inc Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JP5173428B2 (ja) 2004-11-10 2013-04-03 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
EP2230517A1 (de) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (de) 2005-02-23 2013-10-16 Genentech, Inc. Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP1922410A2 (de) 2005-08-15 2008-05-21 Genentech, Inc. Genunterbrechungen, zusammensetzungen und verfahren in verbindung damit
EP1962584A2 (de) 2005-11-21 2008-09-03 Genentech, Inc. Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
BRPI0619118A2 (pt) 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
EP2050335A1 (de) 2006-02-17 2009-04-22 Genentech, Inc. Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
RU2008141912A (ru) 2006-03-23 2010-04-27 Новартис АГ (CH) Противоопухолевые лекарства на основе антител к клеточным антигенам
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
EP2176295B1 (de) 2007-07-16 2014-11-19 Genentech, Inc. Humanisierte anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
SG190596A1 (en) 2008-05-06 2013-06-28 Genentech Inc Affinity matured crig variants
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
PH12012500982A1 (en) 2009-11-30 2019-07-10 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
MA34057B1 (fr) 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
US10208129B2 (en) 2010-12-06 2019-02-19 National Research Council Of Canada Antibodies selective for cells presenting ErbB2 at high density
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CR20250325A (es) 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166352T3 (es) * 1989-08-04 2002-04-16 Schering Ag Dominio externo de c-erbb-2:gp75.

Also Published As

Publication number Publication date
PT616812E (pt) 2000-04-28
DK0616812T3 (da) 2000-04-25
DE69326937D1 (de) 1999-12-09
EP0616812B1 (de) 1999-11-03
DE69326937T2 (de) 2000-12-28
ES2141128T3 (es) 2000-03-16
EP0616812A1 (de) 1994-09-28
GR3032511T3 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
NO20061723L (no) Intercellulaert domene av HER-2/neu-protein for forhindring eller behandling av malignitet
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
BRPI0213223B8 (pt) polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
DK1248643T3 (da) Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
ATE345130T1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DK1368054T3 (da) Anvendelse af neurale trådproteiner til behandling af tumorer
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
RZN Patent revoked